Pipeline

DEVELOPMENT STAGE & ANTICIPATED MILESTONES THERAPEUTIC INDICATION ANTIBODY PROGRAM LEAD OPTIMIZATION IND-ENABLING PHASE 1 PHASE 2 PHASE 3 ANB032: Anti-BTLA Agonist Inflammatory Diseases IND Q4 2022;Initiate Phase 2Trial H1 2023 Rosnilimab (ANB030):Anti-PD-1 Agonist Alopecia Areata AZURE: Top-Line DataQ1 2023 Imsidolimab (ANB019):Anti-IL-36R Generalized PustularPsoriasis ANB033: Anti-CD122 Antagonist Inflammatory Diseases Phase 1 Top-LineData AnouncedApril 2022 IND Submission H1 2024 Top-Line DataQ4 2023